Vaccination against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) represents an important path toward ending the COVID-19 (coronavirus disease 2019) pandemic and alleviating the severity of COVID-19 in most patient populations.1-3 Solid organ transplant recipients are a vulnerable population with significant COVID-19–associated morbidity and mortality.4,5 Initial reports indicate an impaired anti–SARS-CoV-2 antibody response among transplant recipients following mRNA vaccination, likely because of maintenance immunosuppression.